Corient Private Wealth LLC Has $55.49 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Corient Private Wealth LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 15.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 244,579 shares of the medical instruments supplier’s stock after selling 44,773 shares during the period. Corient Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $55,488,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company in the 4th quarter worth $25,000. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at about $29,000. Picton Mahoney Asset Management lifted its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the period. Hopwood Financial Services Inc. bought a new position in Becton, Dickinson and Company during the fourth quarter worth about $39,000. Finally, Versant Capital Management Inc grew its position in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 73 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

BDX opened at $226.43 on Monday. The company has a market capitalization of $65.02 billion, a price-to-earnings ratio of 37.61, a P/E/G ratio of 1.63 and a beta of 0.35. The business’s 50-day moving average price is $232.78 and its two-hundred day moving average price is $232.29. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.84%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler upped their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Finally, Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $278.29.

Insider Buying and Selling

In other news, EVP Richard Byrd sold 1,940 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total value of $436,325.40. Following the completion of the sale, the executive vice president now owns 7,411 shares of the company’s stock, valued at approximately $1,666,808.01. This represents a 20.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,363 shares of company stock worth $1,676,105. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.